ea0099rc5.2 | Rapid Communications 5: Pituitary and Neuroendocrinology | Part I | ECE2024
Boertien Tessel M.
, Drent M.L.
, Booij Jan
, Majoie Charles B.L.M.
, Stokkel Marcel P.M.
, Hoogmoed Jantien
, Pereira Alberto M.
, Biermasz Nienke
, Simsek Suat
, Groote Veldman Ronald
, Weterings Annick J.
, Vink Juan M.
, Tanck Michael W.T. .
, Fliers Eric
, Bisschop Peter H.
Background: Patients with non-functioning pituitary macroadenoma (NFMA) currently have no established medical treatment options. Somatostatin analogues may decrease tumour size, but randomised controlled trials are lacking. In vivo somatostatin receptor assessment with 68Ga-DOTATATE PET could help in selecting patients for treatment. We aimed to determine the effect of the somatostatin analogue lanreotide on tumour size in patients with a 68Ga-DOTATATE PE...